-
AstraZeneca and AI biopharmaceutical company Absci sign $247 million agreement to collaborate on cancer drug development
英国和瑞典的制药公司阿斯利康与美国人工智能(AI)生物制剂公司 Absci 签订了一项价值高达 2.47 亿美元的协议,以设计一种用于对抗抗癌症的抗体,Absci 在周日的一份声明中说。 Absci 与阿斯利康的合作旨在开发一种零次生成 AI 模型,该模型旨在创建新的和改进的抗体治疗法。该公司没有说明他们计划针对哪种类型的癌症。 Absci 应用生成人工智能设计基于目标亲和力、安全性、可制造性和其…- 1.6k
❯
Search
Scan to open current page
Top
Checking in, please wait
Click for today's check-in bonus!
You have earned {{mission.data.mission.credit}} points today!
My Coupons
-
¥CouponsLimitation of useExpired and UnavailableLimitation of use
before
Limitation of usePermanently validCoupon ID:×Available for the following products: Available for the following products categories: Unrestricted use:Available for all products and product types
No coupons available!
Unverify
Daily tasks completed: